NCT07393373
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Enrolling by Invitation
PHASE2Ages 3–18InterventionalTreatmentQED Therapeutics, a BridgeBio company
~135 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Infigratinib
At a glance
Recruiting sites
0 of 24 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment emergent adverse events (TEAE) and serious TEAE
Measured over 10 years
+1 more outcome measured
Conditions
Where it's being run
24 sites across 19 statesFrance3
Ontario2
Norway2
England2
California1
Colorado1
District of Columbia1
Maryland1
Study leadership
- QED Therapeutics SVP, Clinical Development · STUDY_DIRECTOR · QED Therapeutics, a BridgeBio company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of treatment emergent adverse events (TEAE) and serious TEAE10 years
- Changes over time in standing height Z-score in relation to HCH and non-HCH growth charts10 years